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Abstract TRPM8 has been implicated in pain and migraine
based on dorsal root- and trigeminal ganglion-enriched ex-
pression, upregulation in preclinical models of pain, knockout
mouse studies, and human genetics. Here, we evaluated the
therapeutic potential in pain of AMG2850 ((R)-8-(4-
(trifluoromethyl)phenyl)-N-((S)-1,1,1-trifluoropropan-2-yl)-
5,6-dihydro-1,7-naphthyridine-7(8H)-carboxamide), a small
molecule antagonist of TRPM8 by in vitro and in vivo char-
acterization. AMG2850 is potent in vitro at rat TRPM8 (IC90
against icilin activation of 204±28 nM), highly selective
(>100-fold IC90 over TRPV1 and TRPA1 channels), and oral-
ly bioavailable (Fpo>40%).When tested in a skin-nerve prep-
aration, AMG2850 blocked menthol-induced action poten-
tials but not mechanical activation in C fibers. AMG2850
exhibited significant target coverage in vivo in a TRPM8-
mediated icilin-induced wet-dog shake (WDS) model in rats
(at 10 mg/kg p.o.). However, AMG2850 did not produce a
significant therapeutic effect in rat models of inflammatory
mechanical hypersensitivity or neuropathic tactile allodynia
at doses up to 100 mg/kg. The lack of efficacy suggests that
either TRPM8 does not play a role in mediating pain in these
models or that a higher level of target coverage is required.
The potential of TRPM8 antagonists as migraine therapeutics
is yet to be determined.
Keywords TRPM8 . AMG2850 . Pain . Inflammatory .
Neuropathic . Hypersensitivity . Small molecule .
Therapeutic . Rat
Abbreviations
TRPM8 Transient receptor potential melastatin 8
TRPV1 Transient receptor potential vanilloid type 1
TRPA1 Transient receptor potential ankyrin 1
CHO Chinese hamster ovary





The transient receptor potential melastatin 8 (TRPM8) is a
nonselective cation channel known as the Bcool receptor^
stemming from early work describing the cooling-activated
current (Reid and Flonta 2001). Later, the localization of
TRPM8 in subpopulations of small-diameter, cold-sensitive
peripheral sensory neurons confirmed its activation by cool
temperatures or compounds known to evoke cooling sensa-
tions such as menthol and icilin (McKemy et al. 2002; Peier
et al. 2002; Nieto-Posadas et al. 2011). Further evidence of the
role of TRPM8 in thermal sensation and even thermoregula-
tion was generated with TRPM8 knockout (KO) mice.
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TRPM8 KO mice do not show the normal warm temperature
preference that is typical in mice (Dhaka et al. 2006; Bautista
et al. 2007; Colburn et al. 2007; Dhaka et al. 2007; Knowlton
et al. 2010; Knowlton and McKemy 2011) nor do they show
normal adaptive responses to cold or menthol-induced ther-
moregulatory challenges (Tajino et al. 2007, 2011; Almeida
et al. 2012; Gavva et al. 2012).
Recent genome-wide association studies (GWAS) involving
migraine patients have demonstrated a strong association of
TRPM8 with migraine. Single nucleotide polymorphs (SNPs)
within the TRPM8 gene have consistently been found to show a
protective association with migraine in multiple studies as well
as in a meta-analysis of all migraine GWAS suggesting that
TRPM8 modulators may act as migraine therapeutics
(Chasman et al. 2011; Schurks 2011; Freilinger et al. 2012;
Anttila et al. 2013; Esserlind et al. 2013; Chasman et al. 2014).
Besides interest in TRPM8 as a temperature sensor and
target for migraine, it has also been considered as a potential
target for chronic pain based on results in KO mice, receptor
expression, and early pharmacology (Daniels and McKemy
2007; Stucky et al. 2009; Liu and Qin 2011; Malkia et al.
2011; McCoy et al. 2011; Almaraz et al. 2014). KOmice have
also been used to demonstrate a significant role for TRPM8 in
the inflammatory and neuropathic injury-related increases in
cold sensitivity (Colburn et al. 2007; Xing et al. 2007;
Descoeur et al. 2011) and also that TRPM8 is required for
cooling-evoked analgesia (Proudfoot et al. 2006; Dhaka
et al. 2008). TRPM8 expression in free nerve terminals of
skin, and localization in Aδ and C neurons in the dorsal root
and trigeminal ganglia, is consistent with a role in both
thermosensation as well as cold hypersensitivity (McKemy
et al. 2002; Park et al. 2006; Proudfoot et al. 2006;
Fleetwood-Walker et al. 2007; Takashima et al. 2007;
Belmonte et al. 2009; Knowlton and McKemy 2011;
McCoy et al. 2011).
Although delivery of a therapeutic that addresses the clin-
ical need for reduction of cold hypersensitivity in conditions
such as joint pathology or chemotherapy-induced peripheral
neuropathy would be beneficial for a large number of patients,
a drug that additionally mitigates the mechanical hypersensi-
tivity and spontaneous pain in these disorders would have
even broader clinical utility. Thus, TRPM8 upregulation in
preclinical models of pain that are characterized by mechani-
cal hypersensitivity and ongoing pain, including chronic con-
striction injury, complete Freund’s adjuvant (CFA) model, and
oxaliplatin-induced hypersensitivity (Gauchan et al. 2009),
implicates TRPM8 as an ideal target for mediating not only
cold-evoked hypersensitivities but also inflammatory- or
neuropathic-induced pathophysiology itself. As interest in-
creases in TRPM8 as a more widespread pain target (Malkia
et al. 2009; Ferrer-Montiel et al. 2012; Tamayo et al. 2012;
Almaraz et al. 2014; Horne et al. 2014), a large number of
patents for potent TRPM8 antagonists are emerging.
To assess the therapeutic potential of TRPM8 antag-
onists for chronic pain, we characterized AMG2850 as a
potent, selective, orally bioavailable antagonist of




AMG2850, which was synthesized at Amgen Inc (Thousand
Oaks, CA), resulted from an internal medicinal chemistry ef-
fort (Horne et al. 2014). All the cell culture reagents were
purchased from Invitrogen (Carlsbad, CA).
In vitro characterization
Luminescence readout assay for measuring intracellular
calcium
Stable Chinese hamster ovary (CHO) cell lines express-
ing rat TRPA1, rat TRPM8, rat TRPV3, and human
TRPV4 were generated using the tetracycline-inducible
T-REx™ expression system from Invitrogen (Carlsbad,
CA) and a stable CHO cell line expressing rat TRPV1
was generated using a constitutive expression system
(Klionsky et al. 2007). To enable a luminescence read-
out based on intracellular increase in calcium (Le Poul
et al. 2002), each cell line was also co-transfected with
pcDNA3.1 plasmid containing jelly fish aequorin
cDNA. Twenty-four hours before the assay, cells were
seeded in 96-well plates and all TRP channel expres-
sion, except for TRPV1, was induced with 0.5 ug/mL
tetracycline. On the day of the assay, culture media
were removed and cells were incubated for 2 h with
pH 7.2 assay buffer (F12 containing 30 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
for TRPV1, TRPA1, TRPM8, and TRPV3; F12 contain-
ing 30 mM HEPES, 1 mM CaCl2, and 0.3 % BSA for
TRPV4) containing 15 uM coelenterazine (P.J.K GmbH,
Germany). AMG2850 was added 2.5 min prior to the
addition of an agonist. Luminescence was measured by
a CCD camera-based FLASH-luminometer built by
Amgen, Inc. The following agonists were used to acti-
vate TRP channels: 0.5 uM capsaicin for TRPV1,
80 uM allyl isothiocyanate (AITC) for TRPA1, 1 uM
icilin or cold buffer (12 °C) for TRPM8, 200 uM
aminoethoxydiphenyl borate (2-APB) for TRPV3, and
1 uM 4α-phorbol 12,13-didecanoate (4α-PDD) for
TRPV4. Antagonist IC50 values were calculated using
GraphPad Prism 4.01 (GraphPad Software Inc, San
Diego, CA).
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Agonist-induced 45Ca2+ uptake assay
Two days prior to the assay, cells were seeded in Cytostar 96-
well plates (Amersham) at a density of 20,000 cells/well. The
activation of TRPM8 was followed as a function of cellular
uptake of radioactive calcium (45Ca2+) upon cold or icilin
stimulation. To determine the ability to block agonist activa-
tion of TRPM8, AMG2850 was incubated with CHO cells
expressing the TRP channel for 2 min before the addition of
agonist and 45Ca2+ and cells were washed after a further incu-
bation of 2 min to determine the 45Ca2+ uptake. All antagonist
45Ca2+ uptake assays were conducted as reported previously
(Gavva et al. 2007), with a final 45Ca2+ concentration of
10 μCi/mL. Radioactivity was measured using a MicroBeta
Jet (PerkinElmer, Inc.). Data were analyzed using GraphPad
Prism 4.01 (GraphPad Software Inc, San Diego, CA).
Pharmacokinetics in plasma and brain
Plasma pharmacokinetics of each compound inmale Sprague-
Dawley rats (n=3 animals per study) were determined after
intravenous dosing at 2 mg/kg in 100 % dimethylsulfoxide
(DMSO) or after administration of 5 mg/kg by oral gavage
with test article formulated in 5 % Tween 80 in OraPlus®. At
designated time points, blood was collected via the femoral
artery and processed for plasma by centrifugation. Plasma was
then transferred into a 96-well container and stored in a freezer
maintained at −70 °C. Similar bioanalytical methods were
used to determine plasma and brain exposure in animals tested
in pharmacodynamic and pain models. Brain samples were
homogenized with a 4:1 ratio of water (mL) for every gram
of brain tissue. All analytical methods utilized protein precip-
itation, with the addition of a structurally similar compound to
function as an internal standard. Calibration standards were
prepared from a 1 mg/mL stock solution of each compound
in DMSO with a serial dilution into a blank matrix (plasma or
brain homogenate). Liquid chromatography with tandem
mass spectrometry was used for the quantitation of each com-
pound in rat plasma and brain. Non-compartmental pharma-
cokinetic analysis of plasma concentrations was conducted
using WinNonlin Enterprise v.5.1.1 (Pharsight Corporation,
Mountain View, CA). Brain uptake was calculated as a ratio
of concentration in whole brain tissue to that in plasma taken
from the same animal at approximately the same time.
Plasma protein binding
The unbound fraction in plasma was determined by ultracen-
trifugation. Test compound (5 ug/mL) was incubated in plas-
ma from male rats at 37 °C for 15 min. Samples were trans-
ferred to a centrifuge tube and centrifuged at 16,128×g for 3 h
at 37 °C. After protein precipitation using acetonitrile contain-
ing an internal standard (2:1 acetonitrile to plasma),
supernatants were dried under a stream of nitrogen gas, with
residues reconstituted in methanol/water (50:50, v/v) prior to
analysis by liquid chromatography with tandem mass spec-
trometry. The concentration was determined from a linear re-
gression of peak area ratios (analyte peak area/internal stan-
dard peak area) relative to calibration standards. The unbound
fraction in plasma (Cu) was calculated as a ratio of the con-
centration measured relative to the nominal concentration.
Skin nerve preparation and fiber analysis
Adult C57BL/6 mice were obtained from Jackson
Laboratories and used for ex vivo skin-nerve preparations.
Mice were allowed to acclimate to the animal facility at the
Medical College of Wisconsin, an Association for the
Assessment and Accreditation of Laboratory Animal
Committee (AALAC)-accredited facility, for approximately
1 week following shipment. Animals were housed with up
to four other cagemates and had ad libitum access to food
pellets and hyper-chlorinated water. Mice were housed on a
14:10 h light-dark cycle in cages containing aspen bedding
and paper nesting material. Room temperatures averaged
21 °C. Prior to use, animals were briefly anesthetized with
inhaled isoflurane and then sacrificed via cervical dislocation.
All procedures were approved by the Institutional Animal
Care and Use Committee at the Medical College of
Wisconsin.
The mouse saphenous skin-nerve in vitro preparation
(Koltzenburg et al. 1997; Stucky et al. 1999) was used for
electrophysiological recordings of cutaneous terminals of pri-
mary afferent fibers in situ. Recordings were conducted on
adult male C57BL/6 mice, aged 7–18 weeks. Mice were anes-
thetized with isoflurane and sacrificed by cervical dislocation.
The saphenous nerve and skin from the medial dorsum of the
hind paw were then rapidly dissected free and placed corium
side up into a bath superfused with oxygen-saturated synthetic
interstitial fluid containing (in mM) 123 NaCl, 3.5 KCl, 0.7
MgSO4, 1.7 NaH2PO4, 2.0 CaCl2, 9.5 sodium gluconate, 5.5
glucose, 7.5 sucrose, and 10 HEPES, 290 mOsm, at pH 7.45±
0.05, and temperature 32.0±0.5 °C. The saphenous nerve was
desheathed and teased into fine filaments for extracellular re-
cordings, as described (Kwan et al. 2009). Single afferent
units were identified using a mechanical search stimulus
(blunt glass rod). C fibers were identified by conduction ve-
locities slower than 1.2 m/s. Once a unit with a signal to noise
ratio >2 was identified, the mechanical threshold was deter-
mined using calibrated von Frey filaments (range, 0.44–
147.0 mN).
For treatment with TRPM8 inhibitors, the receptive field of
each C fiber was isolated with a metal ring (4-mm diameter)
sealed to the skin and incubated in vehicle (0.1 % DMSO or
0.003 %DMSO) or 10 μMAMG2850 for 10 min. AMG2850
was dissolved to the final concentration in 0.1 % DMSO. A
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baseline recording was taken during the final 2 min of com-
pound incubation to measure any ongoing action potentials.
For mechanical stimulation in the presence of test com-
pounds, the receptive field of each C fiber was tested with a
series of increasingmechanical forces (5, 10, 20, 40, 100, 150,
200, 245 mN; 10-s sustained force; 1-min inter-stimulus inter-
val). For chemical stimulation, the receptive field of each C
fiber was stimulated with 300 μMmenthol in the presence of
the respective compound and action potentials were recorded
for 2 min. C fibers were considered to be responsive to men-
thol if they fired at least three action potentials above baseline
during the 2-min incubation period.
Wave forms of action potentials evoked by mechanical
stimuli were saved on an oscilloscope for comparison of shape
and profile. Data were collected using a Powerlab 4.0 system
and LabChart software (ADInstruments, Colorado Springs,
CO) and saved for off-line analysis. Action potentials were
discriminated and counted off-line using a spike histogram
software extension. For C fibers that exhibited ongoing activ-
ity in the presence of TRPM8 inhibitors, the frequency of
action potentials during baseline was subtracted from action
potentials evoked during mechanical or menthol stimulation.
The operator was blinded to chemical treatment applied to
each receptive field. All data was also analyzed in a blinded
manner.
In vivo pharmacodynamic and pain models
Adult male Sprague-Dawley rats weighing 220–300 g
(Harlan, San Diego) were cared for in accordance to the
Guide for the Care and Use of Laboratory Animals, 8th
Edition (National Research Council Committee for the
Update of the Guide for the C and Use of Laboratory A
2011). Animals were group housed at an Association for
Assessment and Accreditation of Laboratory Animal
Committee-accredited facility in non-sterile ventilated micro-
isolator housing on corn cob bedding. All research protocols
were approved by the Institutional Animal Care and Use
Committee. Animals had ad libitum access to pelleted feed
(Harlan Teklad 2020X, Indianapolis, IN) and water (on-site
generated reverse osmosis) via automatic watering system.
Animals were maintained on a 12:12 h light-dark cycle in
rooms at 21±3 °C, 50±20 % room humidity, and had access
to enrichment opportunities (nesting materials and plastic
domes). All animals were sourced from approved vendors
who meet or exceed animal health specifications for the ex-
clusion of specific pathogens (i.e., mouse parvovirus,
Helicobacter). Animals were allowed at least 1-week acclima-
tion to the facility prior to any procedures. Following comple-
tion of behavioral or blood pressure measurements, animals
were euthanized with carbon dioxide followed by immediate
blood collection via cardiac puncture for pharmacokinetic
analysis. All behavioral data was scored by an observer blind
to dosing condition or through an automated device.
Icilin-induced wet-dog shake (WDS) model
The TRPM8 antagonist (1, 3, or 10 mg/kg) or vehicle control
(5 % Tween 80 in OraPlus®) was administered p.o. 90 min
prior to administration of icilin (0.5 mg/kg, 1 ml/kg, i.p.,
100 % PEG 400). The number of shakes exhibited by the rats
(wet-dog shakes; WDS) was counted for a duration of 30 min
post icilin administration (Werkheiser et al. 2006). Rats were
viewed through transparent Plexiglas® observation cylinders
that were placed on a custom, opaque, plastic apparatus such
that one rat could not view another rat. The 0.5 mg/kg dose of
icilin was chosen based on an in-house dose-response effect
over 0.3–1.0 mg/kg in which nonlinear dose-response curve
analysis yielded a goodness of fit r2 of 0.84, and the resulting
ED90 was 0.46 mg/kg (0.28–0.75; data not shown).
Cold-induced increase in blood pressure—cold pressor test
(CPT)
Rats were treated with the TRPM8 antagonist (0.3, 1, or
3 mg/kg) or vehicle control (5 % Tween 80 in OraPlus®)
p.o. 2 h prior to anesthesia with sodium pentobarbital at
60 mg/kg i.p. Blood pressure was recorded for 5 min for
Bpre-cold baseline^ and an additional 5 min during immersion
of the paws and ventral half of the body in ice water. Mean
blood pressure (MBP) was derived electronically using Digi-
Med Blood Pressure Analyzer (Model 400). Plasma was col-
lected through the artery catheter immediately after the cold
pressor test for pharmacokinetic analysis. Percent increase
from baseline and percent inhibition attributed to treatment
with test compound were then determined using the following
formula: (1) percent increase from baseline (mmHg) cold
pressor effect=[(cold-evoked change in MBP)/MBP pre-
cold]×100; (2) percent inhibition of cold pressor effect=[1−
(cold-evoked change in MBP post-test compound/cold-
evoked change in MBP post-vehicle)]×100.
Open field activity
Rats were habituated in a reversed light cycle room in home
cages for at least 1 week and acclimated to the testing room for
1 h prior to dosing. TRPM8 antagonist (10, 30, or 100 mg/kg)
or vehicle (5%Tween 80 inOraPlus®) was injected 2 h before
placing an animal in the open-field apparatus. Open-field ac-
tivity was measured using a system that counts interruptions
of a set of photobeams for the course of 60 min (Kinder
Scientific, Poway, CA). To begin a session, animals were re-
moved from the home cage and placed individually into an
independent Plexiglas box (41 cm L×41 cm W×38 cm H)
surrounded by a frame consisting of 32 photocells (16Y and
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16X) that track the movement of the animal. Photobeam
breaks were used as an indication of activity and were mea-
sured as the following parameters per minute: basic move-
ments (beam breaks), distance traveled (cm), time spent (s),
and number of repetitive beam breaks (i.e., stereotypic move-
ment). Chlordiazepoxide, which consistently elicits a decrease
in open field activity, was used as a positive control.
Chlordiazepoxide was formulated in saline at 5.6 mg/kg i.p.
and dosed 30 min before the start of the open field assay.
CFA-induced hypersensitivity
Rats were habituated in a reversed light cycle room for at least
1 week and to the testing room for 1 h prior to dosing. To
begin the study, rats received an injection of CFA into the left
hind paw (100 μL of 0.1 % CFA in saline) based on previous
demonstration that this causes a decrease in rearing. Since this
rearing deficit can be significantly reversed by treatment with
indomethacin, it is presumed to represent mechanical and/or
tactile hypersensitivity and rats are rearing less in order to
avoid weight bearing on the inflamed hindpaw (Youngblood
et al. 2008). Twenty-one hours after the CFA injection, ani-
mals were treated (p.o.) with vehicle (5 % Tween 80 in
OraPlus®) or TRPM8 antagonist. Two hours after drug dosing
(23 h after CFA injection), rats were placed in the sameKinder
Scientific open field boxes as described above but with cus-
tomized prickly floor inserts placed inside. Rearing time and
rearing counts were measured for 60 min. Indomethacin at a
dose of 1 mg/kg dosed p.o. in 5 % Tween 80 in OraPlus® was
chosen as a positive control based on reliable efficacy demon-
strated in previous experiments (Youngblood et al. 2008).
Sciatic nerve ligation (SNL)-induced tactile allodynia
SNL surgery was performed using aseptic surgical tech-
niques and a stereomicroscope (Kim and Chung 1992).
Spinal nerve injury was caused by ligating the left L5
and L6 spinal nerves, with special care to avoid damage
to the L4 spinal nerve or surrounding area. More specifi-
cally, under gaseous anesthesia with a mixture of O2 and
isoflurane (3 % for induction and 2 % for maintenance),
skin was excised and the longissimus lumborum muscle,
part of articular processes (L4-S1), and the fascia above
L6 spinal nerve were carefully removed. This procedure
provided a clean and spacious working area to enable
complete resection of the L6 transverse process and to
separate the L5 spinal nerve from the L4 spinal nerve
without damage to L4. The L5 and L6 spinal nerves were
each tightly ligated with 6-0 silk thread and then L5 was
cut. The entire surgery procedure beginning from anesthe-
sia and ending with wound clipping of the outside skin
lasted 15 min or less.
Surgical procedure
Behavioral testing Two weeks post surgery, mechanical sensi-
tivity was measured by determining the median 50 % foot
withdrawal threshold for von Frey filaments using the up-
down method (Chaplan et al. 1994). Rats were placed under
a plastic cover (9×9×20 cm) on a metal mesh floor. von Frey
filaments (Semmes-Weinstein monofilaments from Stoelting)
were applied to the middle glabrous area between the footpads
of the plantar surface of the injured hind paw. This plantar area
was touched with a series of nine recently calibrated von Frey
filaments with approximately exponentially incremental bend-
ing forces (von Frey filament numbers 3.61, 3.8, 4.0, 4.2, 4.41,
4.6, 4.8, 5.0, and 5.2; equivalent to 0.41, 0.63, 1.0, 1.58, 2.51,
4.07, 6.31, 10, and 15.8 g). The von Frey filament was pre-
sented perpendicular to the plantar surface with sufficient force
to cause slight bending and held for approximately 3–4 s. To
avoid possible reflex responses, only abrupt withdrawal of the
foot accompanied by pain indicative behaviors (namely paw
flinching, shaking, or licking for more than 2 s) was recorded
as a response. Any post-surgery rat that displayed amechanical
threshold of more than 3.16 g or less than 0.7 g was eliminated
from the study. After measuring basal threshold, animals were
treated (p.o.) with vehicle (5 % Tween 80 in OraPlus®) or
TRPM8 antagonist (AMG2850 at 100 mg/kg), or gabapentin
(200 mg/kg; Sigma, St. Louis). The measurement of the tactile
threshold was reassessed at 1 and 2 h after drug administration
in the same animals.
Statistical analyses
In vivo IC50 and IC90 estimates using WDS model data
were determined by fitting a sigmoidal dose-response
curve to individual animal number of WDS versus
resulting plasma concentration. Behavioral and electro-
physiological data are expressed as mean±standard error
of the mean (S.E.M.). Results were analyzed using one-
way analysis of variance (ANOVA) with Dunnett’s
multiple-comparisons post-hoc test for significance rela-
tive to vehicle. Since the von Frey filament set was
calibrated on a logarithmic scale by the vendor
(Stoelting), our selection of nine filaments for the up-
down method was also based on near-equal logarithmic
intervals (Dixon 1980), and because it is our experience
that variability noticeably increases with threshold value
and also variances are statistically different using
Bartlett’s test of equal variances, thus violating the as-
sumptions of ANOVA, data were analyzed following
logarithmic transformation prior to statistical analysis.
Actual gram values are plotted on a logarithmic scale
Y-axis of the figures for convenience. Statistical calcula-
tions and graphs were made using GraphPad Prism 5.01
(GraphPad Software Inc, San Diego, CA). Percent
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responders to menthol stimulation in the ex vivo skin-nerve
preparation were compared under vehicle and antagonist con-
ditions through the use of Fisher’s exact test. Responses of C
fibers to increasing mechanical forces under vehicle or antag-
onist conditions were compared using a two-way ANOVA
with a Bonferonni post-hoc analysis.
Results
AMG2850 acts as a potent and selective TRPM8 antagonists
in vitro
TRPM8 antagonist hits were identified by high through-
put screening of compound libraries and subsequent me-
dicinal chemistry efforts yielded AMG2850 (Horne et al.
2014). AMG2850 blocks both icilin and cold activation of
rat TRPM8 potently. The IC50 estimates of AMG2850 are
41±8 nM against cold activation and 204±28 nM against
icilin activation assays (Fig. 1a). AMG2850 is >600-fold
selective for TRPM8 versus TRPA1 and >100-fold selec-
tive for TRPM8 over rat TRPV1, rat TRPV3, and human
TRPV4 (see Table 1).
AMG2850 exhibits suitable pharmacokinetic properties
for in vivo studies
AMG2850 exhibited good pharmacokinetic properties in-
cluding low plasma clearance 0.47 L/h/kg and good oral
bioavailability 47 % in male Sprague-Dawley rat (see
Table 1). Total brain to plasma ratio of AMG2850 is in
the range of 0.8–1.5 which demonstrates brain uptake and
would be expected to provide coverage if there are brain
TRPM8 channels that play a role in pain. We have used
unbound plasma concentrations (Cu; also sometimes
referred to as Bexposure^) in calculating the target cover-
age since Bprotein-bound^ fraction of compounds are con-
sidered unavailable for TRPM8 occupancy.
AMG2850 blocks menthol-evoked activation of C fibers
in mouse
In order to better understand how the TRPM8 antagonists
affect primary afferent firing, we assessed the effects of these
compounds in an ex vivo skin-nerve preparation. First, it was
assessed whether the compounds could block a TRPM8 ago-
nist response. We focused on C fibers as most TRPM8-
expressing afferents are C fibers (Bautista et al. 2007). C fibers
treated with the vehicle control (0.1 % DMSO) responded to
menthol (300 μM) with action potential firing (8.6±2.9 action
potentials per 2 min). In contrast, pretreatment with
AMG2850 (10 μM) completely inhibited all menthol-
evoked firing (n=22; p=0.005; Fig. 1b) demonstrating that
AMG2850 completely blocks chemical activation of
TRPM8 on cutaneous nerve terminals in situ.























von Frey-induced action potentials
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TRPM8 inhibition has no effect on mechanically induced
firing in cutaneous C fibers
AMG2850 (10μM)was evaluated inmechanical activation of
cutaneous C fibers following a range of increasing, sustained
force in the presence of the vehicle or TRPM8 antagonist.
AMG2850 had no significant effect on mechanical firing in
C fibers compared to vehicle controls (Fig. 1c). The C fibers
treated with vehicle or AMG2850 did not differ in average
conduction velocity or von Frey mechanical thresholds (data
not shown). These data indicate that the TRPM8 channel does
not contribute to mechanical firing following von Frey stim-
ulation in cutaneous C fiber nociceptors.
AMG2850 dose-dependently inhibits icilin-induced WDS
in rats
To choose the icilin concentration for reversal studies, the
number of WDS was evaluated following 0.3, 0.5. 0.75, and
1 mg/kg of icilin. As shown in Fig. 2a, the ED80 is just less
than 0.5 mg/kg. In the experiments that evaluated AMG2850,
0.5 mg/kg of icilin showed a comparable 137±27WDS in the
vehicle-treated groups. AMG2850 exhibited dose-dependent
and full prevention of icilin-induced WDS (Fig. 2b). Full
Fig. 1 a AMG2850 potently inhibits both cold temperature- and icilin-
induced increase in luminescence believed to reflect intracellular calcium
in CHO cells stably expressing rat TRPM8. After a 2-h incubation with
coelenterazine, cells were incubated with compounds for 2.5 min prior to
the addition of either icilin (1 μM) or cold buffer (12 °C). Luminescence
was measured by a CCD camera-based FLASH-luminometer.
Concentration-response curves were generated using GraphPad Prism
4.01. Each point in the graphs is an average±SEM of an experiment
conducted in triplicate. Responses of agonists used were normalized to
100 % of maximum. b In a skin-nerve preparation, total percentage of C
fibers responding to 300 μM menthol after incubation with vehicle or
AMG2850. A response to menthol was defined as three action potentials
above baseline over a 2-min interval. Incubation with AMG2850
significantly decreased the percentage of C fibers responding to
menthol as compared to vehicle controls (**p<0.005). c In a skin-nerve
preparation, AMG2850 has no effect on C fiber firing in response to
sustained mechanical force of increasing intensities. Note an increasing
number of action potentials with increased force that is not altered by
preincubation of AMG2850






rTRPM8 (cold) IC90 (nM) 41±8
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Fig. 2 a Intraperitoneal injection of icilin induces wet-dog shakes
(WDS) in a dose-dependent manner. b AMG2850 reduces WDS in a
dose- and plasma concentration-dependent manner. c AMG2850
(10 mg/kg, p.o.) significantly and fully blocked the cold pressor effect
(***p<0.001)
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prevention occurred at 10 mg/kg with a Cu of 192±26 nM and
calculated unbound mean in vivo IC90 value of 99 nM.
AMG2850 suppresses cold-induced increase in blood
pressure
Since TRPM8 can be activated by cold in addition to icilin, we
evaluated a dose near theWDS ED90 of AMG2850 in the cold
pressor model (CPT; Fig. 2c). When tested at 10 mg/kg,
AMG2850 also fully blocked the cold pressor response with
a resulting Cu of 488±48 nM.
AMG2850 did not affect open field activity
While assessing the potential analgesic effects of a compound,
conclusions could be confounded if compounds also produce
sedative or motor side effects, resulting in false positives.
Thus, prior to testing in pain behavioral models, we evaluated
AMG2850 in the open field assay along with a positive con-
trol of 5.6 mg/kg chlordiazepoxide (CDP; Fig. 3a). When
AMG2850 was administered at 100 mg/kg (mean Cu concen-
tration was of 2.59 μM), total distance traveled was 13,640±
623 cm, which was not significantly different relative to the
vehicle-treated group (14,484±1686 cm; F3,20=1.0, p>0.05).
As expected, total distance traveled was significantly reduced
to 9423±745 cm in rats receiving chlordiazepoxide (t10=2.8,
p<0.05; Fig. 3a).
AMG2850 did not reverse CFA-induced mechanical
hypersensitivity
We previously validated an automated, high-throughput assay
to measure spontaneous/ongoing mechanical hypersensitivity
(Youngblood et al. 2008). In this assay, rats injected with CFA
to one hindpaw show a decrease in rearing behavior as mea-
sured 24 h later in an open field apparatus with a prickly floor
insert. This window of presumed hypersensitivity behavior
can be reversed by standard nonsteroidal anti-inflammatory
drugs (Youngblood et al. 2008). In addition to automated
scoring, a key advantage of this model is that reduction of
pain behavior is quantified as a recovery of normal rearing
instead of a decrease in an evoked response; thus, compounds
that reduce general movement would not falsely be interpreted
as efficacious.
In the experiment to evaluate the effects of AMG2850,
there was also a significant window of hypersensitivity as
measured by the rearing time response of animals adminis-
tered with CFA in the hindpaw (204±21 s) as compared to
vehicle control in the hindpaw (525±35 s; t38=7.9, p<0.01).
There was an overall significant effect on hypersensitivity (F3,
36=4.6) with the reduction in rearing inhibited by 1 mg/kg
indomethacin (388±32 cm; p<0.05 by Dunnett’s multiple
comparisons; Fig. 3b). AMG2850 dosed at 100 mg/kg
produced no significant effect on rearing time relative to ve-
hicle (157±25 s; p>0.05 by Dunnett’s multiple comparisons;
Fig. 3b) despite a mean Cu plasma concentration of 4.3 μM.
AMG2850 did not reverse SNL-induced tactile allodynia
Two weeks post SNL surgery, rats exhibited a tactile threshold
of 4.4±1.2 g (vehicle-administered group; Fig. 3c). A loga-
rithmic transformation of the data was performed prior to
analysis, though actual g values are referred to in the text
and shown on graphs. By Dunnett’s multiple-comparisons test
relative to vehicle control, the positive control, gabapentin,
significantly reversed SNL-induced mechanical allodynia
with a significant increase in the threshold to 12.4±1.2 g
(F2,31=11.99, p<0.05). AMG2850 at 100 mg/kg p.o. pro-
duced no significant effect on von Frey threshold relative to
vehicle (p>0.05) with tactile threshold of 5.8±1.3 g. The
mean Cu plasma concentration in this group was 2.1 μM.
Discussion
Here, we report the pharmacology of AMG2850 as a potent
and selective antagonist of TRPM8 channels in vitro and
in vivo. AMG2850 demonstrated significant TRPM8 antago-
nism in vivo in two distinct target coverage models (icilin-
induced wet-dog shake behavior (WDS) and cold-induced
blood pressure increase in CPT model). AMG2850 signifi-
cantly blocked menthol-induced, but not mechanically in-
duced, activation of C fibers in situ. AMG2850 did not show
efficacy in either the CFAmodel of mechanical hypersensitiv-
ity or the SNL-induced tactile allodynia model of neuropathic
pain at plasma unbound concentrations in excess of 21-fold of
an IC90 concentration in the TRPM8-specific WDS model.
This suggests that either TRPM8 does not play a role in me-
chanical pain behaviors measured or a much higher target
coverage is required for efficacy. Here, we discuss the results
of this study in the context of antagonist exposure in vivo and
TRPM8 function in different in vivo models.
Fig. 3 a AMG2850 did not affect the total distance traveled in reversed
light cycle rat open field boxes (p>0.05) while the positive control
compound chlordiazepoxide (CDP; 5.6 mg/kg) significantly reduced
distance traveled (*p<0.05). b Unilateral hindpaw injection of complete
Freund’s adjuvant (CFA) causes a reduction in rearing behavior. The
positive control indomethacin (indo; 1 mg/kg) significantly
(++++p<0.0001) reversed the CFA-induced reduction in rearing
behavior. AMG2850 (100 mg/kg) produced no significant effect
(*p>0.05). c SNL produces a reduction in tactile threshold from
approximately 15 g to approximately 5 g. The positive control,
gabapentin (200 mg/kg), significantly reversed the reduction in tactile
threshold (**p<0.01). AMG2850 (100 mg/kg) produced no significant
effect at 2.5 h post treatment (p>0.05)
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Comparison of exposure in different models: relationship
to target coverage and efficacy
Protein unbound concentrations of antagonists are used for
comparison between different studies. In the WDS in vivo
target coverage model, resulting unbound IC90 value for
AMG2850 is 99 nM. Compared to the WDS IC90 value, un-
bound concentration of AMG2850 in CFA and SNL models
was 43- and 21-fold higher, respectively, than the WDS IC90
value. Lack of efficacy in both CFA and SNL models with
unbound concentrations in excess of 21-fold the IC90 cover-
age inWDSmodel either suggests that IC90 coverage inWDS
model is an underestimate of actual target coverage or TRPM8
does not play a role in pain behaviors measured in these
models.
BMolecular sensors^ such as TRPM8 (a cold temperature
sensor) play a role in body temperature homeostasis by induc-
ing autonomic and behavioral cold defenses upon activation
by either cold or chemical ligands (Almeida et al. 2012; Gavva
et al. 2012). WDS behavior induced by icilin probably repre-
sents a skeletal muscle-mediated heat generation mechanism
and such a response may only need activation of a small sub-
population of TRPM8 channels; hence, target coverage mea-
sured in WDS model may be an underestimate relative to
target coverage required in pain models in which TRPM8
channels are reportedly upregulated.
A second potential underestimation could come from the
way the icilin dose is chosen for an antagonist evaluation.
Typically, an ED80 of an agonist dose is identified based on
a dose response assuming that the behavioral endpoint such as
WDS is linear. However, behavioral endpoints may not be
linear due to different reasons such as physical limitations,
resulting in a lower ED80 value that may not cover the target
at 80 % occupancy. This may be the case with AMG2850
where 0.5-fold of in vitro IC90 concentration is equivalent to
WDS IC90 concentration.
Role of TRPM8 antagonists on cold sensing and cold
hypersensitivity
The role of TRPM8 in cold sensing and cold hypersensitivity
is unequivocally proven with KO mouse studies as well as
with antagonists (Knowlton et al. 2011; McCoy et al. 2011;
Parks et al. 2011; Patel et al. 2014). In particular, TRPM8
antagonists representing different chemotypes such as com-
pound 496 (Parks et al. 2011), PBMC (Knowlton et al.
2011), and M8-An (Patel et al. 2014) attenuated cold hyper-
sensitivity after CFA or peripheral nerve injury models sug-
gesting that TRPM8 antagonists may act as therapeutics for
indications where cold hypersensitivity is an issue such as
chemotherapy and other neuropathic conditions. Although
we have not tested antagonists in these models, the overlap
between published results and our studies is that TRPM8 an-
tagonists cover the target in WDS model as well as suppress
cold-induced increase in blood pressure (CPT model).
Additionally, electrophysiological data generated using an
ex vivo skin-nerve preparation demonstrates that AMG2850
is effective in blocking C fiber action potentials evoked by a
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endpoints, whether at baseline, post-inflammatory, or post-
neuropathic, appear to serve as additional target coverage
models for TRPM8 antagonists and are separable from effica-
cy models with non-cold endpoints.
TRPM8 role in tactile allodynia
While initial reports using TRPM8 KO mice indicated that
TRPM8 is not involved in mechanical sensitivity (Bautista
et al. 2007; Knowlton et al. 2013), another study found
increased von Frey thresholds among C fibers in exogenous
skin-nerve preparations taken from TRPM8 KO mice as
compared to wild-type controls (Zimmermann et al.
2011). Additionally, behavioral studies using icilin or men-
thol have also shown that agonist activation of TRPM8 may
cause sensitization or desensitization/inhibition of re-
sponses to mechanical stimuli under naïve conditions
(Brignell et al. 2008; Klein et al. 2010; Harrington et al.
2011) or after injury (Proudfoot et al. 2006; Brignell et al.
2008; Su et al. 2011; Liu et al. 2013). However, we ob-
served no effect of AMG2850 on mechanical sensitivity
using both inflammatory and neuropathic pain models, de-
spite a robust effect on cold behaviors. Additionally,
ex vivo teased fiber recordings indicated no effect of
AMG2850 on mechanical sensitivity from naïve C fibers.
Thus, two possibilities exist: either TRPM8 does not play a
role in mechanosensation before or after injury, or
AMG2850 binds TRPM8 in such a way as to inhibit ligand
activation by menthol, but not its role in mechanosensation.
Regardless, it can be concluded that AMG2850 is not an
effective modulator of mechanical hypersensitivity or tac-
tile allodynia, despite target coverage in vivo.
Although many have suggested TRPM8 as a thera-
peutic target for chronic pain, there are no examples of
TRPM8 antagonists that reverse non-cold-evoked behav-
ioral endpoints of inflammatory or neuropathic pain.
One recent example is M8-An, a potent small molecule
antagonist of TRPM8 shown to attenuate SNL-induced
cold hypersensitivity, but was shown to be ineffective at
reducing tactile allodynia (Patel et al. 2014). Similarly,
AMG2850 potently blocks cold-induced physiological
changes but not inflammatory- or neuropathic-induced
non-cold endpoints such as mechanical hypersensitivity
or tactile allodynia.
An indication for which antagonism of TRPM8 may still
hold therapeutic promise is migraine, though the lack of val-
idated preclinical migraine models leaves the promise to be
revealed in the clinic. Additional indications for which new
data is emerging such as urogenital diseases and pathophysi-
ologies related to lacrimation, airway, and vasculature await
further evaluation (for recent reviews, see Knowlton and
McKemy 2011; Liu and Qin 2011; Malkia et al. 2011;
Almaraz et al. 2014).
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